Left Atrial Appendage Occlusion Clinical Trial
Official title:
LAmbre Versus AMPLATZER Amulet Left AtrIal Appendage Occluder for StRoke ProphylaxIs: The Randomized AMPIRI Trial
The objective of this trial is to compare two different commercially available left atrial appendage occlusion (LAAO) devices in patients with non-valvular Atrial fibrillation/ atrial flutter (AF) at increased risk for stroke with regard to safety and efficacy. The investigators hypothesize that LAAO using the LAmbre occlusion device (Lifetech Scientific, Shenzhen, China) is non-inferior to LAAO using the AMPLATZER Amulet occlusion device (Abbott Medical, Chicago, ILL, USA) with regards to the primary endpoint, which is peri-device leak (PDL) size 3 months after LAAO, as assessed with transesophageal echocardiography (TOE) in patients with non-valvular AF.
AMPIRI is an investigator-initiated, prospective, randomized, multi-center, open-label, non-inferiority other clinical investigation. All consecutive patients with non-valvular AF at increased risk for stroke or systemic embolism based on CHA2DS2-VASc score not eligible for long-term oral anticoagulation therapy will qualify for screening. Patients with confirmed eligibility and who have given written informed consent will be randomized in a 1:1 fashion to group A (LAmbre LAAO device) or group B (AMPLATZER Amulet LAAO device). Clinical indication, technique, and timing of LAAO will be at the operator's discretion. The investigators hypothesize that LAAO using the LAmbre occlusion device (Lifetech Scientific, Shenzhen, China) is non-inferior to LAAO using the AMPLATZER Amulet occlusion device (Abbott Medical, Chicago, ILL, USA) with regards to the primary endpoint, which is PDL size 3 months after LAAO, as assessed with TOE in patients with non-valvular AF. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03987945 -
Left Atrial Appendage Occlusion in Patients With Non-valvular Atrial Fibrillation From Shanghai
|
||
Completed |
NCT05632445 -
Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
|
Phase 4 | |
Terminated |
NCT00841529 -
Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage
|
Phase 2 | |
Recruiting |
NCT05554822 -
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
|
Phase 3 | |
Not yet recruiting |
NCT04897204 -
Left Atrial Appendage Electrical Isolation in Persistent Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04524741 -
Use of Intracardiac Echocardiography or Left Atrial Appendage Radiography to Guide Implantation of a Left Atrial Appendage Occlusion Device
|
N/A | |
Recruiting |
NCT04524780 -
Use of Intracardiac Echocardiography or Left Atrial Appendage Radiography to Guide Implantation of a Left Atrial Appendage Occlusion Device.
|
N/A | |
Withdrawn |
NCT05399342 -
Left Atrial Appendage Occlusion Study III Extended Follow Up
|
||
Completed |
NCT05136417 -
Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device
|
N/A | |
Recruiting |
NCT05671276 -
Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion
|
Phase 4 | |
Recruiting |
NCT04502017 -
Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
|
Phase 4 |